公开(公告)号：US11813236B2

公开(公告)日：2023-11-14

申请号：US17471780

申请日：2021-09-10

Applicant: SCANDIBIO THERAPEUTICS AB

Inventor： Adil Mardinoglu ,  Jan Borén ,  Mathias Uhlén

IPC: A61K31/198 ,  A61P1/16 ,  A61K31/205 ,  A61K31/706

CPC classification number: A61K31/198 ,  A61K31/205 ,  A61K31/706 ,  A61P1/16

Abstract: There is provided a composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammnoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate, wherein the molar ratio of A) to D) is between 250:1 and 1.5:1 and the molar ratio of A) to B) is between 16:1 and 1:4. The composition may be used in a method of treatment of a medical condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance and dyslipidemia.

公开(公告)号：US20230355609A1

公开(公告)日：2023-11-09

申请号：US18092723

申请日：2023-01-03

Applicant: Quixgen, Inc.

Inventor： Yusheng Xiong ,  Hong-Ping Guan ,  Wenjun Huang

IPC: A61P17/10 ,  A61K31/145 ,  A61K31/18 ,  A61K31/192 ,  A61K31/444 ,  A61K31/65 ,  A61K47/32 ,  C07D491/107 ,  A61P3/04 ,  A61K9/00 ,  A61K31/575 ,  A61K31/616 ,  A61K31/7056 ,  A61K38/26 ,  A61K31/4709 ,  A61K31/197 ,  A61K31/203 ,  A61K31/401 ,  A61K31/438 ,  A61K47/10 ,  A61P1/16 ,  A61K31/40 ,  A61K31/4164 ,  A61K31/7048 ,  A61K48/00 ,  C07D519/00

CPC classification number: A61K31/4709 ,  A61K9/0014 ,  A61K31/145 ,  A61K31/18 ,  A61K31/192 ,  A61K31/197 ,  A61K31/203 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4164 ,  A61K31/438 ,  A61K31/444 ,  A61K31/575 ,  A61K31/616 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/26 ,  A61K47/10 ,  A61K47/32 ,  A61K48/005 ,  A61P1/16 ,  A61P3/04 ,  A61P17/10 ,  C07D491/107 ,  C07D519/00

Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

公开(公告)号：US20230348482A1

公开(公告)日：2023-11-02

申请号：US18027990

申请日：2022-01-13

Applicant: Universidad Autonoma De Madrid ,  Consejo Superior De Investigaciones Cientificas ,  Universidad Miguel Hernandez De Elche ,  Fundacion De Investigacion Biomedica Del Hospital Universitario De La Princesa

Inventor： Antonio Cuadrado Pastor ,  Raquel Fernandez Gines ,  Jose Antonio Encinar ,  Rafael Leon Martinez ,  Juan Felipe Franco Gonzalez ,  Manuela Garcia Lopez ,  Maria Isabe Rodriguez Franco ,  Ana Isabel Rojo Sanchis

IPC: C07D487/20 ,  A61P1/16 ,  G01N33/50

CPC classification number: C07D487/20 ,  A61P1/16 ,  G01N33/5008

Abstract: The present invention relates to NRF2-βTrCP interaction inhibitors with general formula I and its derivate salts for use in the treatment of NRF2-related diseases caused by chronic inflammation and oxidative stress. More specifically the present invention relates to NRF2-βTrCP interaction inhibitors with specific formula I and its derivate salts for treating diseases of the liver related with chronic inflammation and oxidative stress, such as fatty liver disease.

公开(公告)号：US11802293B2

公开(公告)日：2023-10-31

申请号：US17072676

申请日：2020-10-16

Applicant: KING'S COLLEGE LONDON ,  ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Ralph Michael Linden

IPC: C12N15/86 ,  C07K14/005 ,  A61P27/02 ,  A61P27/06 ,  A61P1/16 ,  A61P25/00 ,  A61K48/00

CPC classification number: C12N15/86 ,  A61K48/0008 ,  A61P1/16 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06 ,  C07K14/005 ,  C12N2750/14122 ,  C12N2750/14142 ,  C12N2750/14143

Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.

公开(公告)号：US11793862B2

公开(公告)日：2023-10-24

申请号：US17814594

申请日：2022-07-25

Applicant: CUROGEN TECHNOLOGY CO., LTD. ,  RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY

Inventor： Chang Woo Lee ,  Jin Kwan Lee ,  Hyun Soo Kim ,  Ji Hyun Choi ,  Se Eun Byeon ,  Hae In Lee ,  Hyeonju Jo

IPC: A61K38/46 ,  A61K48/00 ,  A61P1/16

CPC classification number: A61K38/465 ,  A61K48/0008 ,  A61K48/0058 ,  A61P1/16

Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.

公开(公告)号：US20230332151A1

公开(公告)日：2023-10-19

申请号：US18298287

申请日：2023-04-10

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Fatemeh Momen HERAVI ,  Akiva MINTZ

IPC: C12N15/113 ,  A61K47/69 ,  A61K47/64 ,  A61P1/16

CPC classification number: C12N15/113 ,  A61K47/6425 ,  A61K47/6911 ,  A61P1/16 ,  C12N2310/113 ,  C12N2310/3231 ,  C12N2320/32

Abstract: The present disclosure relates to methods and compositions for preventing and/or treating liver fibrosis, liver cancer, and/or liver disease. In particular, the present disclosure relates methods and compositions which to decrease or inhibit microRNA found to be upregulated in liver fibrosis, liver cancer, and/or liver disease, or increase or activate microRNA found to be downregulated in liver fibrosis, liver cancer and/or liver disease. The present disclosure also relates to the use of engineered exosomes or extracellular vesicles in the methods and compositions for targeted delivery of the agents to the liver.

公开(公告)号：US20230330166A1

公开(公告)日：2023-10-19

申请号：US18336973

申请日：2023-06-17

Applicant: Guangdong Xinghai Biotechnology Co., Ltd. ,  Guangdong Xinghai Institute of Cell

Inventor： Jincheng Zeng ,  Shaobing Zhang

IPC: A61K35/747 ,  A61P3/06 ,  A61P3/10 ,  A61P1/16 ,  C12N1/20

CPC classification number: A61K35/747 ,  A61P3/06 ,  A61P3/10 ,  A61P1/16 ,  C12N1/205 ,  C12R2001/225

Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.

公开(公告)号：US20230321179A1

公开(公告)日：2023-10-12

申请号：US18020908

申请日：2021-08-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Oren Rom ,  Jifeng Zhang ,  Yuqing Eugene Chen ,  Ying Zhao

IPC: A61K38/06 ,  A61P1/16 ,  A61K31/198 ,  A61P9/10

CPC classification number: A61K38/06 ,  A61K31/198 ,  A61P1/16 ,  A61P9/10

Abstract: The present invention relates to N-acyl amino acid products and their use in diagnosing and treating disease.

公开(公告)号：US20230310431A1

公开(公告)日：2023-10-05

申请号：US18040614

申请日：2021-08-04

Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDTION, YONSEI UNIVERSITY

Inventor： Kyung-Hee Chun ,  Jung-Hwan Baek

IPC: A61K31/506 ,  A23L33/00 ,  A61P1/16 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K31/506 ,  A23L33/30 ,  A61P1/16 ,  G01N33/5044 ,  G01N33/6893 ,  G01N2800/085 ,  G01N2333/96425

Abstract: The present invention relates to a pharmaceutical composition or a functional food composition for preventing or treating a liver disease selected from the group consisting of steatohepatitis, hepatic fibrosis and cirrhosis. A triazole derivative compound discovered in the present invention reduces collagen accumulation in liver tissue and significantly inhibits the expression of inflammatory factors. Thus, the triazole derivative compound effectively blocks the progression of a series of severe liver diseases, from excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to a decrease in the number of hepatocytes and loss of liver function, unlike conventional drugs that have only a simple lipid-lowering effect. Accordingly, the triazole derivative compound may be useful as a composition for fundamental treatment of liver fibrosis and cirrhosis.

公开(公告)号：US11771737B2

公开(公告)日：2023-10-03

申请号：US16756926

申请日：2018-10-29

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Tim F. Greten ,  Chi Ma

IPC: A61K38/14 ,  A61P1/16 ,  A61P35/00 ,  A61K31/4985 ,  A61K31/575 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K38/14 ,  A61K31/4985 ,  A61K31/575 ,  A61K39/39541 ,  A61P1/16 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  C07K2317/76

Abstract: In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of vancomycin and a checkpoint inhibitor. In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of a primary bile acid.